iX Biopharma Ltd. (SG:42C) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
iX Biopharma Ltd has revealed a pharmacokinetic study indicating that their SL-NAD+ wafer can effectively deliver NAD+ directly into cells via sublingual administration, challenging previous assumptions about NAD+ cellular entry. The study showed rapid absorption with significant bioavailability, suggesting a convenient alternative to IV therapy for NAD+ supplementation. These findings position SL-NAD+ as a potentially superior method for enhancing NAD+ levels without relying on precursors.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.
